Genetics and treatment of actinic prurigo in Thailand
Part of Skin clinical trials.
This study looks at the genetics of actinic prurigo (a sun-sensitive rash) and how thalidomide affects it. It may help find better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be of Thai ethnicity.
- You must have been diagnosed with actinic prurigo (a sun-triggered rash) by the study's criteria.
- You must be mentally able to understand and follow the study instructions in Thai.
- If you take thalidomide, you must use two types of birth control (like pills and condoms) starting 4 weeks before and continuing during and 4 weeks after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a new drug works in people with actinic keratosis (rough, scaly patches caused by sun damage) on their upper arms or face. You will receive the treatment and have blood samples taken to see how your body processes the medication.
This trial tests a new oral medication called ACT-777991 to see if it is safe and can help repigment skin in adults with non-segmental vitiligo (the most common type that affects both sides of the body). Participants must have at least a certain amount of pigment loss on the face and total body, and agree not to use other vitiligo treatments during the study.
This trial tests an experimental drug called ICP-332 for people with prurigo nodularis (a condition causing very itchy, hard bumps on the skin). It aims to see if the drug can safely reduce itching and improve skin lesions.
This trial tests an oral drug called erlotinib (an EGFR inhibitor) in adults with certain genetic skin disorders. It aims to reduce symptoms of thickened, blistering or scaly skin. You may be able to join if you have a confirmed genetic form of these conditions and your skin is moderately affected.
This trial tests an investigational gel called HW211026 for people with actinic keratosis, a common precancerous skin condition. It aims to see if the gel is a safe and effective treatment for lesions on the face.
This trial tests a special light treatment (photobiomodulation) to see if it can safely reduce itch. It compares the treated area to a similar untreated area on your body.
Hear when a new Actinic Prurigo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.